Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimens

Area of Science:

• Virology
• Immunology
• Pharmacology

Background:

• Interferon-beta (IFN-beta) is a key antiviral cytokine.
• Understanding the molecular mechanisms of IFN-beta efficacy is crucial for optimizing treatment.
• Frequent dosing strategies may enhance antiviral responses.

Purpose of the Study:

• To elucidate the molecular mechanism behind the enhanced antiviral efficacy of frequent interferon-beta (IFN-beta) dosing.
• To compare the effects of twice-daily versus once-daily IFN-beta administration on hepatitis C virus (HCV) dynamics and gene expression.

Main Methods:

• A randomized study of 140 patients with HCV receiving either 3 MU IFN-beta twice daily or 6 MU once daily.
• Serial analysis of serum HCV RNA levels.
• Quantification of double-stranded RNA-activated protein kinase (PKR) and MxA mRNA in peripheral blood mononuclear cells (PBMC).

Main Results:

• Twice-daily IFN-beta resulted in a 2-fold greater rate of HCV decline during the second phase compared to once-daily dosing (P=0.04).
• While peak PKR and MxA expression was higher in the once-daily group initially, the twice-daily group maintained significantly higher expression in the second phase.
• Basal PBMC PKR and MxA expression strongly correlated with liver tissue levels (r=0.81 and r=0.75, respectively; P<0.0001).

Conclusions:

• Twice-daily IFN-beta dosing enhances the elimination of HCV-infected cells.
• This improved efficacy is linked to sustained, higher intracellular expression of PKR and MxA during the treatment's second phase.
• The findings support optimized dosing regimens for improved antiviral outcomes.